APA (7th ed.) Citation

Hsu, H., Liu, Y., Wang, C., Chou, W., Hsu, Y., Chiang, J., . . . Yang, T. (2019). Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer. Cancer Medicine, 8(7), 3437. https://doi.org/10.1002/cam4.2235

Chicago Style (17th ed.) Citation

Hsu, Hung‐Chih, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin, and Tsai-Sheng Yang. "Sequential Cetuximab/bevacizumab Therapy Is Associated with Improved Outcomes in Patients with Wild‐type KRAS Exon 2 Metastatic Colorectal Cancer." Cancer Medicine 8, no. 7 (2019): 3437. https://doi.org/10.1002/cam4.2235.

MLA (9th ed.) Citation

Hsu, Hung‐Chih, et al. "Sequential Cetuximab/bevacizumab Therapy Is Associated with Improved Outcomes in Patients with Wild‐type KRAS Exon 2 Metastatic Colorectal Cancer." Cancer Medicine, vol. 8, no. 7, 2019, p. 3437, https://doi.org/10.1002/cam4.2235.